LARIN 1.5/30 Drug Patent Profile
✉ Email this page to a colleague
When do Larin 1.5/30 patents expire, and when can generic versions of Larin 1.5/30 launch?
Larin 1.5/30 is a drug marketed by Novast Labs and is included in one NDA.
The generic ingredient in LARIN 1.5/30 is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LARIN 1.5/30?
- What are the global sales for LARIN 1.5/30?
- What is Average Wholesale Price for LARIN 1.5/30?
Summary for LARIN 1.5/30
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 3 |
| DailyMed Link: | LARIN 1.5/30 at DailyMed |
US Patents and Regulatory Information for LARIN 1.5/30
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novast Labs | LARIN 1.5/30 | ethinyl estradiol; norethindrone acetate | TABLET;ORAL-21 | 202996-001 | Mar 20, 2014 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
